Report
Pharmaceuticals: Read across from Amgen’s Q3 figures for European companies
PharmaceuticalsRead across from Amgen’s Q3 figures for European companies
An overall beat to the Q3 numbers
Old legacy products are more resilient than expected
Amgen’s own biosimilars help offset the group’s own impact
Disappointing Repatha and Aimovig
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Eric Le Berrigaud
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.